Compare Davita Inc (DVA) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs T-Mobile Us Inc — how do they compare? Davita Inc trades at $181.49 (market cap $11.38B), while T-Mobile Us Inc trades at $176.86 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 16.8× Davita Inc's market cap, and T-Mobile Us Inc pays a 2.28% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TMUS | |
|---|---|---|
Market Cap | $11.38B | $191.56B |
Sector | Health | Media |
52-Week High | $240.96 | $259.01 |
52-Week Low | $103.87 | $167.65 |
Enterprise Value | $24.10B | $308.17B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
TMUS trades at $176.21, down 1.09% over 24 hours, with a bearish technical signal but strong fundamentals including Q2 2026 EPS beat of $2.99 vs. $2.59 expected. Revenue grew to $88.31B in 2025, with net income of $10.99B and robust cash flow from operations of $27.95B. Recent news highlights spectrum sales and competitive threats from SpaceX's Starlink Mobile.
The outlook is mixed: analyst consensus is bullish with an $233.20 price target, but rising debt and SpaceX competition pose risks. Earnings growth and dividend increases support long-term value, though near-term volatility may persist due to technical bearishness and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
